Healthy Extracts Inc. | 10-Q: FY2026 Q1 Revenue: USD 1.611 M

Revenue: As of FY2026 Q1, the actual value is USD 1.611 M.EPS: As of FY2026 Q1, the actual value is USD -0.01.EBIT: As of FY2026 Q1, the actual value is USD -243.8 K.Overview and StrategyHealthy Extracts Inc. focuses on acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals, targeting categories such as heart, brain, and immune health. The company’s mission is to acquire or create products with health and performance benefits that have mass consumer appeal. The acquisition of Gummy USA in October 2025 accelerated revenue growth and increased gross profit, while also adding contract manufacturing and formulation services. Healthy Extracts Inc. operates through its subsidiaries: BergaMet NA, LLC (nutraceutical heart and immune health products), UBN (nutraceutical products for brain health), and HE Gummy USA, Inc. (manufacturing). Future Outlook and StrategyManagement plans to continue seeking funding through debt and equity financing to support growth and research and development of new products. The company expects revenue growth to increase as direct consumer sales and marketing efforts continue to perform. Healthy Extracts Inc. had a net loss from inception to December 31, 2025, of - $20,121,462 and limited cash resources of $146,935 at December 31, 2025, which raises doubt about its ability to continue as a going concern. Consolidated Financial Performance (Three Months Ended March 31, 2026 vs. 2025)Revenue: Healthy Extracts Inc. reported revenues of $1,610,744 for the three months ended March 31, 2026, an increase of $679,464 or 73% compared to $931,280 for the same period in 2025. Cost of Revenue: The cost of revenue was $622,043 for the three months ended March 31, 2026, up by $115,748 or 23% from $506,295 in the prior year period. Cost of revenue as a percentage of revenues decreased to 39% in 2026 from 54% in 2025. Gross Profit: Gross profit increased by $563,716 or 61% to $988,701 for the three months ended March 31, 2026, from $424,985 in the corresponding period of 2025. Operating Expenses: General and administrative expenses were $1,317,403 for the three months ended March 31, 2026, a 147% increase from $533,833 in 2025, primarily due to additional salaries and wages and stock-based compensation expense recognition. Other Income (Expense): Other income (expense) was $128,112 for the three months ended March 31, 2026, compared to - $290,011 for the same period in 2025, an increase of $418,123 or 144%. This included interest expense, net of interest income of - $84,907, a change in fair value on derivative of $283,019, and a gain/loss of disposal of assets of - $70,000 in 2026. In 2025, it consisted of interest expense of - $34,558 and a change in fair value on derivative of - $255,454. Net Income (Loss): The net loss decreased to - $200,590 for the three months ended March 31, 2026, from - $398,860 for the three months ended March 31, 2025. Segmented Financial Information (Three Months Ended March 31, 2026)Revenue:Consolidated: $1,610,744 BergaMet: $869,892 Gummy USA: $740,852 UBN: $0 Corporate: $0 Cost of Revenue:Consolidated: $622,043 BergaMet: $406,472 Gummy USA: $214,697 UBN: $0 Corporate: $0 Gain (Loss) Before Income Tax:Consolidated: - $200,590 BergaMet: - $54,922 Gummy USA: - $232,440 UBN: - $498 Corporate: $87,270 Long-lived Assets:Consolidated: $526,647 BergaMet: $19,154 Gummy USA: $4,766 UBN: $502,727 Corporate: $0 Identifiable Assets:Consolidated: $520,752 BergaMet: $453,377 Gummy USA: $67,375 UBN: $0 Corporate: $0 Depreciation and Amortization:Consolidated: $156,168 BergaMet: $893 Gummy USA: $155,275 UBN: $0 Corporate: $0 Segmented Financial Information (Nine Months Ended December 31, 2025)Revenue:Consolidated: $4,511,997 BergaMet: $3,751,247 Gummy USA: $760,750 UBN: $0 Corporate: $0 Cost of Revenue:Consolidated: $2,433,103 BergaMet: $2,219,096 Gummy USA: $214,007 UBN: $0 Corporate: $0 Gain (Loss) Before Income Tax:Consolidated: - $881,119 BergaMet: $53,408 Gummy USA: - $154,242 UBN: - $300 Corporate: - $779,985 Long-lived Assets:Consolidated: $1,140,342 BergaMet: $186,978 Gummy USA: $450,637 UBN: $502,727 Corporate: $0 Identifiable Assets:Consolidated: $843,357 BergaMet: $737,862 Gummy USA: $105,495 UBN: $0 Corporate: $0 Depreciation and Amortization:Consolidated: $152,192 BergaMet: $1,963 Gummy USA: $150,229 UBN: $0 Corporate: $0 Liquidity and Capital ResourcesCash Position: Cash on hand was $164,385 as of March 31, 2026. Operating Cash Flow: Net cash provided by operating activities was $105,970 for the three months ended March 31, 2026, compared to $60,021 for the same period in 2025. Investing Activities: Net cash used in investing activities was $0 for both the three months ended March 31, 2026, and 2025. Financing Activities: Net cash used in financing activities was - $88,520 for the three months ended March 31, 2026, compared to - $53,243 for the same period in 2025. This included $176,000 from the issuance of notes payable, offset by payments for repayment of notes payable of - $110,492 and convertible debt repayments of - $106,000 in 2026. Current Assets and Liabilities: Total current assets decreased by - $239,238 to $1,088,079 as of March 31, 2026, from $1,327,317 at December 31, 2025. Total current and total liabilities decreased by - $457,860 to $3,337,239 as of March 31, 2026, from $3,795,099 at December 31, 2025. Subsequent EventsOn April 30, 2026, Healthy Extracts Inc. agreed to a secured loan of $140,000 with a cost of funds equal to 9.2% or $152,880, due upon acceptance. On May 5, 2026, secured debt M was paid off in full.